J&J Looks To Broaden Spine Offerings, Considers DTC Ads For Charité
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson is pursuing alternate spinal technologies to address Charité artificial lumbar disc limitations, which are hindering adoption of the device as a stand-alone, total spine treatment
You may also be interested in...
Drug-eluting stent study
Guidant has received FDA permission to expand the SPIRIT III trial of its Xience V everolimus-eluting stent to the full cohort of 1,292 patients at up to 80 sites. The trial compares the Xience V, built on Guidant's cobalt-chromium Multi-Link Vision platform, with Boston Scientific's Taxus paclitaxel-eluting stent. The trial began in May (1"The Gray Sheet" May 9, 2005, p. 12)...
Drug-eluting stent study
Guidant has received FDA permission to expand the SPIRIT III trial of its Xience V everolimus-eluting stent to the full cohort of 1,292 patients at up to 80 sites. The trial compares the Xience V, built on Guidant's cobalt-chromium Multi-Link Vision platform, with Boston Scientific's Taxus paclitaxel-eluting stent. The trial began in May (1"The Gray Sheet" May 9, 2005, p. 12)...
Carotid Stent, AAA Market Entry: Boston Scientific Moves On Earn-Outs
Boston Scientific intends to acquire carotid stent manufacturer EndoTex by year-end, following an anticipated FDA approval of NexStent